Trial · NCT07886775
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 30
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Any stroke or death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months | 6 months | This outcome includes ischemic/hemorrhagic stroke or all-cause death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months. |
| Secondary | Any stroke or death from enrollment to 30 days after endovascular treatment of the qualifying artery | 30 days | Ischemic/hemorrhagic stroke or all-cause death from enrollment to 30 days after endovascular treatment of the qualifying artery. |
| Secondary | Any ipsilateral stroke or death within 3 months after enrollment | 3 months | Ipsilateral ischemic/hemorrhagic stroke or all-cause death within 3 months after enrollment. |
| Secondary | Any contralateral stroke within 3 months after enrollment | 3 months | Contralateral ischemic/hemorrhagic stroke within 3 months after enrollment. |
| Secondary | Neurological improvement assessed by mRS at 3 months | 3 months | Modified Rankin Scale (mRS score) ranged from 0 to 6 is used to measure the recovery of neurological function in patients after stroke. Score 0 means completely no symptom. Score 6 means death. Higher values represent a worse outcome. |
| Secondary | Any ipsilateral stroke or death within 6 months after enrollment | 6 months | Ipsilateral ischemic/hemorrhagic stroke or all-cause death within 6 months after enrollment. |
| Secondary | Any contralateral stroke within 6 months after enrollment | 6 months | Contralateral ischemic/hemorrhagic stroke within 6 months after enrollment. |
| Secondary | Ischemic driven qualifying artery revascularization within 6 months after enrollment | 6 months | Ischemic driven qualifying artery revascularization within 6 months after enrollment. |
| Secondary | Neurological improvement assessed by mRS at 6 months | 6 months | Modified Rankin Scale (mRS score) ranged from 0 to 6 is used to measure the recovery of neurological function in patients after stroke. Score 0 means completely no symptom. Score 6 means death. Higher values represent a worse outcome. |
| Secondary | Restenosis of the qualifying artery within 6 months | 6 months | Restenosis is defined as rate of stenosis \>70% or increased by 30% based on following-up neurovascular imaging. |
| Secondary | Combined vascular events within 6 months after enrollment | 6 months | Combined vascular events include stroke, myocardial infarction and vascular death. Myocardial infarction occurs when blood stops flowing properly to a part of the heart, and the heart muscle is injured because it is not receiving enough oxygen; vascular death means the death is due to vessel rupture or clot. |
| Secondary | Quality of life assessment (EuroQol-5-Dimensions Scale [EQ-5D] questionnaire) at 6 months after enrollment | 6 months | Quality of life evaluated by EuroQol-5-Dimensions Scale (EQ-5D) questionnaire at the 6 months follow-up. EQ-5D descriptive system covers five dimensions including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three response levels (no problem, some problems, and severe problems). The EQ-5D descriptive system generates 243 health states, each of which was assigned a utility. score ranging from -0.59 to 1.00 (full health). |
| Secondary | Any ipsilateral stroke or death within 12 months after enrollment | 12 months | Ipsilateral ischemic/hemorrhagic stroke or all-cause death within 12 months after enrollment. |
| Secondary | Any contralateral stroke within 12 months after enrollment | 12 months | Contralateral ischemic/hemorrhagic stroke within 12 months after enrollment. |
| Secondary | Ischemic driven qualifying artery revascularization within 12 months after enrollment | 12 months | Ischemic driven qualifying artery revascularization within 12 months after enrollment. |
| Secondary | Neurological improvement assessed by mRS at 12 months | 12 months | Modified Rankin Scale (mRS score) ranged from 0 to 6 is used to measure the recovery of neurological function in patients after stroke. Score 0 means completely no symptom. Score 6 means death. Higher values represent a worse outcome. |
| Secondary | Restenosis of the qualifying artery within 12 months | 12 months | Restenosis is defined as rate of stenosis \>70% or increased by 30% based on following-up neurovascular imaging. |
| Secondary | Combined vascular events within 12 months after enrollment | 12 months | Combined vascular events include stroke, myocardial infarction and vascular death. Myocardial infarction occurs when blood stops flowing properly to a part of the heart, and the heart muscle is injured because it is not receiving enough oxygen; vascular death means the death is due to vessel rupture or clot. |
| Secondary | Any ipsilateral stroke or death within 24 months after enrollment | 24 months | Ipsilateral ischemic/hemorrhagic stroke or all-cause death within 24 months after enrollment. |
| Secondary | Any contralateral stroke within 24 months after enrollment | 24 months | Contralateral ischemic/hemorrhagic stroke within 24 months after enrollment. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07886775/registered